Global Health Limited (NSE: Medanta, BSE: 543654) has reported its strongest first-quarter performance to date, underscoring the healthcare sector’s resilience amid rising demand for advanced medical services. For Q1 FY26, total income climbed 19.1% year-on-year to ₹10,513 million, EBITDA rose 22.6% to ₹2,553 million, and Profit After Tax jumped 49.6% to ₹1,590 million. Margins improved to 15.1% for PAT and 24.3% for EBITDA.
Growth was driven by a 13.3% increase in occupied bed days, 4% growth in ARPOB to ₹66,584, and strong patient inflow—up 14.2% for in-patients and 13.1% for out-patients. Mature hospitals earned ₹7,006 million in revenue, while developing hospitals expanded by 35.9% to ₹3,219 million. International patient revenue surged 33.8% to ₹636 million, complemented by a 21.6% rise in OPD pharmacy sales.
Medanta’s planned Northeast expansion could be economically transformative. Currently, many patients travel to Guwahati or Kolkata for tertiary care, creating an outbound healthcare spend. A Medanta presence in the region could retain this expenditure locally, stimulate private healthcare investment, and generate ancillary economic activity in diagnostics, pharmaceuticals, and hospitality. CEO Pankaj Sahni highlighted the operational launch of Ranchi’s 110-bed hospital and the upcoming 550-bed Noida facility as part of a sustained expansion strategy.
